Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis

Review included 136 articles and amongst the findings, was that switching to another tumour necrosis factor inhibitor (TNFi) or non-TNFi bDMARDs after TNFi treatment failure is efficacious, and biosimilars are non-inferior to their reference products.

SPS commentary:

This was one of two systematic literature reviews that informed the EULAR updated recommendations. The review on safety confirmed the known safety profile of biological DMARDs, except for the possibly increased risk of venous thromboembolism with JAK inhibitors, which needs further evaluation.


Annals of the Rheumatic Diseases

Resource links:

EULAR 2019 recommendations

Systematic review (safety)